Send us Feedback

Sanofi-Aventis SA (SNY)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

SNY » Topics » Other long-term investments

This excerpt taken from the SNY 20-F filed Apr 11, 2005.

Other long-term investments

 

Other long-term investments comprise:

 

(in millions of euros)

   

December 31,

2004

    December 31,
2003
   

December 31,

2002

Other long-term investment securities

    380    34    24

Long-term receivables and other deferred charges

    549    74      49
    
  
  

Total (net)

    929    108    73
    
  
  

 

As of December 31, 2004, the main investment lines included in “Other long-term investment securities” were as follows (net values):

 

  •   Rhodia (€100 million): This interest, acquired by sanofi-aventis on the acquisition of Aventis, represents 15.31% of the capital of Rhodia after the 2004 increase in capital to which Aventis subscribed.

 

  •   ProStrakan (€42 million): This 18.75% interest was acquired following a merger in August 2004 between Proskelia, a research company 37.5% owned by Aventis, and Strakan.

 

179

Table of Contents

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Year ended December 31, 2004

 

  •   Millennium (€40 million): This interest was acquired by sanofi-aventis on the acquisition of Aventis. There is a research collaboration agreement with Millennium.

 

  •   Drakkar Holdings (€24 million): This interest was acquired by Aventis on conversion of a convertible debt issue. Drakkar Holdings controls the animal nutrition company Adisseo.

 

  •   Interests in companies with which sanofi-aventis has collaboration agreements in research and development, such as IDM (€21 million) and Regeneron (€19 million); see note D.20.3.

 

  •   Interests in research and development companies such as Transkaryotic Therapies (€26 million), Introgen (€26 million) and Proteome Science Plc (€16 million).

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki